Prescription drug · ANDA
Rifampin NDC 67046-1605
Rifampin 150 mg/1 · Capsule · Oral · Coupler LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 67046-1605-3 | 6704616050367046160503 | 30 CAPSULE in 1 BLISTER PACK (67046-1605-3)Marketed from Oct 13, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Rifampin
- Generic name (nonproprietary)
- rifampin
- Active ingredients
- Rifampin — 150 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Coupler LLCNDC labeler code 67046
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 064150
- Marketing start
- Listing expires
- Other FDA classes
- Rifamycins (Chemical structure)
- Identifiers
- Product ID 67046-1605_410a5d00-f97a-0307-e063-6294a90a9a68SPL ID 410a5d00-f97a-0307-e063-6294a90a9a68SPL set ID 410a314f-83bf-d9b3-e063-6294a90a872cRxCUI 198201UNII VJT6J7R4TR
- Pharmacologic class
- Rifamycin Antibacterial
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N467046160503followed by a unit qualifier and the quantityPackage 67046-1605-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regim…
Excerpt only. Read the full label for complete information.
About NDC 67046-1605
- What is NDC 67046-1605?
- 67046-1605 is the product NDC for Rifampin, Rifampin 150 mg/1 capsule, listed with the FDA by Coupler LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Rifampin.
- What is the active ingredient?
- Rifampin.
- Who is the labeler?
- Coupler LLC, NDC labeler code 67046. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Rifampin?
- 18 other product NDCs are listed under this name. See all Rifampin NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Rifampin products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Rifampin | Rifampin 150 mg/1 | CapsuleOral | ANI Pharmaceuticals, Inc. | 70954-892 | 70954-0892-1070954-0892-20 |
| Rifampin | Rifampin 300 mg/1 | CapsuleOral | ANI Pharmaceuticals, Inc. | 70954-893 | 70954-0893-1070954-0893-2070954-0893-30 |
| rifampin | Rifampin 300 mg/1 | CapsuleOral | Major Pharmaceuticals | 0904-7315 | 00904-7315-61 |
| Rifampin | Rifampin 150 mg/1 | CapsuleOral | PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS | 24658-801 | 24658-0801-30 |
| Rifampin | Rifampin 300 mg/1 | CapsuleOral | PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS | 24658-802 | 24658-0802-60 |
| Rifampin | Rifampin 300 mg/1 | CapsuleOral | EPIC PHARMA, LLC | 42806-799 | 42806-0799-0142806-0799-0542806-0799-30+1 more |
| Rifampin | Rifampin 150 mg/1 | CapsuleOral | EPIC PHARMA, LLC | 42806-801 | 42806-0801-0142806-0801-30 |
| Rifampin | Rifampin 300 mg/1 | CapsuleOral | American Health Packaging | 60687-586 | 60687-0586-01 |
| Rifampin | Rifampin 150 mg/1 | CapsuleOral | American Health Packaging | 60687-575 | 60687-0575-21 |
| Rifampin | Rifampin 600 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9230 | 00143-9230-01 |
Other NDCs under ANDA 064150
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Rifampin | Rifampin 150 mg/1 | CapsuleOral | EPIC PHARMA, LLC | 42806-801 |
| Rifampin | Rifampin 300 mg/1 | CapsuleOral | EPIC PHARMA, LLC | 42806-799 |
| Rifampin | Rifampin 300 mg/1 | CapsuleOral | PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS | 24658-802 |
| Rifampin | Rifampin 150 mg/1 | CapsuleOral | PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS | 24658-801 |